Background: Vessel wall inflammation, atherosclerosis and hypercoagulability may be responsible for ischemic events in Takayasu arteritis (TA). No study has evaluated the effect of antiplatelet therapy for the prevention of ischemic events in TA.
akayasu arteritis (TA) is a chronic idiopathic large vessel vasculitis that affects the aorta and its main branches. Vessel inflammation may lead to arterial wall thickening, stenosis, occlusions or aneurysm formation. 1, 2 Although previously thought to be a rare exotic disease of young Asian women, nowadays it is known to afflict individuals with a wide variety of ethnic backgrounds around the world. 3 Systemic manifestations, pain over the affected arteries and symptoms and signs of regional ischemia from stenotic or occluded arteries are the main manifestations of TA. 1,2,4
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A hypercoagulable state has been described in TA patients that places thrombosis as a concern in the affected vessels with stenotic/occlusive lesions or even aneurysms and may result in acute ischemic events. 5 TA patients presented higher levels of platelet P-selectin and plasma thromboxane B2 (TXB2) and lower levels of 6-keto-PGF1α, specially in those with an active phase who in turn had an enhancement in platelet aggregation in response to collagen. 6-8 Chronic antiplatelet therapy has been recommended in TA patients provided that aspirin is capable of inhibiting platelet aggregability irrespective of soluble CD40 ligand levels (a proinflammatory and prothrombotic marker) and in TA patients it was shown that a daily dosage of 80 mg of aspirin is effective for the suppression of TXB2, but not of prostacyclin in surface-damaged blood vessels. 9-12 However, to date no observational study has proven the efficacy of long-term antiplatelet therapy in the prevention of acute ischemic events in TA patients.
In the present study, we evaluated whether the chronic use of antiplatelet or anticoagulant therapy was associated with a protection against acute ischemic events in TA patients.
Methods
A retrospective observational study was conducted with the Antiplatelet Therapy in Takayasu Arteritis review of medical records of forty-eight patients who fulfilled the 1990 American College of Rheumatology criteria for TA and were under regular follow-up at the Vasculitis Unit in the Universidade Federal de São Paulo (Unifesp). 13 All of the 52 TA patients registered at our Vasculitis Unit were screened for this study, but 4 of them had to be excluded due to incomplete medical records. Medical appointments were scheduled within every one to 3 months in order to evaluate patients for the activity and progression of TA. Blood samples were collected before each visit for complete blood counts, erythrocyte sedimentation rates, lipid profiles, fasting glucose, liver enzymes and renal function. The decision to prescribe aspirin was made by the assistant physician. Statins were prescribed when serum low-density lipoprotein (LDL) levels exceeded 130 mg/dl.
The present study was approved by the Institutional Ethics Committee. We collected information about demographic characteristics, disease features, arteriographic classification of TA, risk factors for cardiovascular diseases (CVD), acute ischemic events and medication used by the patients, including corticosteroids, immunosuppressive drugs, statins, anticoagulant and antiplatelet therapy. 14 The commencement dates for antiplatelet and anticoagulant therapy and of acute ischemic events were collected carefully. Time since the onset of symptoms suggestive of TA, disease duration, bleeding complications of antiplatelet and anticoagulant therapy and deaths were also recorded.
Acute myocardial infarction, unstable angina, transient ischemic attack and stroke, acute limb ischemia and acute intestinal ischemia were considered as acute ischemic events. Stable angina pectoris, mesenteric angina, venous thrombosis and the presence of arterial thrombus without ischemic manifestations were not included in this category.
Traditional risk factors for CVD were ascertained according to NCEP-ATP III and included: age >55 years for women and >45 years for men, current cigarette smoking, hypertension (blood pressure ≥140×90 mmHg or the use of antihypertensive drugs), diabetes mellitus, obesity (body mass index >30 kg/m 2 ), family history of premature CVD, serum LDL >130 mg/dl and serum high-density lipoprotein (HDL) <40 mg/dl. 15, 16 The number of TA patients who presented at least one risk factor for CVD and its mean number were recorded.
The objective of the present study was to evaluate whether the use of antiplatelet or anticoagulant therapy was associated with protection against acute ischemic events in TA patients. Variables that might influence the occurrence of ischemic events such as disease features of TA, risk factors for CVD, use of statins, prednisone and immunosuppressive therapy were also analyzed.
Statistical Analysis
Statistical analysis was carried out with the SPSS (Statistical Package for the Social Sciences) 10.0 for Windows, Chicago, USA. Numerical data was presented as mean or median followed by standard deviation (SD) or 95% confidence interval (95%CI). Categorical data was presented as total number and percentage of cases. Comparison between groups was performed using Student's t-test or Mann-Whitney test for continuous variables and chi-square test or Fisher's exact test for categorical data.
A Kaplan-Meier curve estimator was built to analyze eventfree time with regard to acute ischemic events in patients with and without antiplatelet therapy and the log rank test was used to compare whether the difference was significant or not. The Cox hazard proportional regression model was used to analyze whether antiplatelet therapy, use of anticoagulants, statins or immunosuppressive drugs, delay in TA diagnosis, number of risk factors for CVD, modification of TA arteriographic type during follow-up and HDL were associated or not with an increased risk of ischemic events. Results were expressed as a hazard ratio and 95%CI. The significance level accepted was 5% (P<0.05). Table 1 shows demographic data and clinical characteristics of the 48 TA patients participating in the present study. TA patients were under follow-up in the Vasculitis Unit of Unifesp for a mean of 76.5 months (95%CI: 58.5-94.5). Most TA patients presented angiographic type V at diagnosis (54.2%) and study end (64.6%). At diagnosis, the number of patients according to arteriographic type was: type I (11), IIa (4) IIb (4), III (2), IV (1) and type V (26) . Only 8 patients (16.7%) changed arteriographic type during the disease follow-up. At study end, the number of patients according to arteriographic type was: type I (9), IIa (2), IIb (3), III (1), IV (2) and type V (31). Prednisone was used by 89.6% and immunosuppressive drugs were prescribed for 91.7% of TA patients. Vascular surgical procedures were done in 20 (41.7%) cases and 16 of them (80%) had arteriographic type V. Three deaths (6.3%) occurred during follow-up, one due to pyelonephritis and sepsis, another due to acute myocardial infarction with cardiogenic shock and other patient due to a massive stroke.
Results

Patients' Characteristics and Disease Features
Risk Factors for CVD
Risk factors for CVD were present in 44 (91.7%) TA patients and the mean was 1.86 (95%CI 1.61-2.11). The most common risk factors were systemic hypertension (77.1%), high LDL (45.8%) and obesity (16.7%). The frequency of other risk factors such as diabetes, advanced age, family history of premature coronary artery disease, low HDL and tobacco use was lower than 10% for each of them. Statins were used by 43.8% of patients and they were indicated mostly because of high LDL.
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aspirin was used by 29 patients and ticlopidine by one patient who had presented allergy to aspirin. The median aspirin daily dose was 200 mg, with 100 mg being the lowest and 500 mg the highest daily dose. A daily aspirin dose of 100 mg was used by 13 patients, 200 mg by 12 patients, 325 mg by 3 patients and 500 mg by only one patient with TA. The majority of patients on antiplatelet therapy (86.6%) used a daily aspirin dose between 100 and 200 mg. One patient was using both aspirin and clopidogrel in combination. Anticoagulant therapy was used by 6 (12.5%) patients, among them warfarin was prescribed for 4 patients while phenprocoumon was prescribed for 2 patients. They were indicated for deep venous thrombosis and aorta metallic cardiac valve prosthesis in 3 patients each. No TA patient used antiplatelet and anticoagulant therapy simultaneously during the study. Bleeding complications occurred in 3 (6.2%) patients, 2 of them associated with phenprocoumon and one with aspirin. Gastrointestinal bleeding and hemorrhagic acute abdomen due to the rupture of an ovarian cyst occurred in patients on phenprocoumon whereas massive vaginal bleeding occurred in one patient on aspirin therapy taking 100 mg per day and it was attributed to a uterine myoma.
Acute ischemic events were observed in 14 (29.2%) TA patients. Ischemic stroke and transient ischemic attack were found in 4 (8.3%) and in 3 (6.3%) TA patients, respectively. Acute myocardial infarction occurred in 6 (12.5%) and unstable angina in 2 (4.2%) cases. Twelve patients with ischemic events had angiographic type V and the other 2 patients had type I when they developed stroke. No TA patient presented acute limb ischemia or acute intestinal ischemia.
Other intermittent ischemic manifestations attributed to arterial stenosis but not to arterial thrombosis were abdominal angina found in 2 (4.2%) and stable angina pectoris in other 2 (4.2%) TA patients. Two patients had ischemic events after the onset of symptoms suggestive of TA, but before the diagnosis of TA and the follow-up in our vasculitis unit. One of them had a stroke at 7 months after diagnosis and another had an acute myocardial infarction one year before TA diagnosis.
TA patients with and without acute ischemic events had similar age at diagnosis (30.6±11.9 vs 28.5±10.1 years, P= 0.699) and similar frequency of female gender (92.9% vs 88.2%, P=1.000) and of being Caucasian (50.0% vs 64.7, P=0.344). In the study, TA patients with and without acute ischemic events had similar time since the onset of TA symptoms (118.9±101.3 vs 148.8±107.8 months, P=0.324), time since TA diagnosis (74.3±52.7 vs 115.5±82.7 months, P=0.123) and delay in diagnosis (44.7±87.7 vs 34.2±68.4 months, P=0.616) ( Table 2) .
TA patients who developed acute ischemic events used significantly less antiplatelet agents (14.3%) than those without ischemic events (82.4%), P<0.0001. There was no significant difference concerning the use of anticoagulant therapy, prednisone, immunosuppressive drugs or anti-TNFα agents between patients with or without ischemic events. The prevalence of individual risk factors for CVD and their mean number were similar in patients with and without acute ischemic events. The 3 deaths of TA patients were observed only in those who had presented with acute ischemic events (P=0.021) ( Table 2) . 
Antiplatelet Therapy in Takayasu Arteritis
Figure shows that on the Kaplan-Meier curve, patients with antiplatelet therapy presented with less acute ischemic events during this time (P<0.0001). A Cox hazard proportional regression model demonstrated that antiplatelet therapy was associated with a decreased risk of acute ischemic events over time (hazard ratio=0.055, 95%CI: 0.06-0.514; P=0.011) ( Table 3) .
Discussion
In the present study we observed that chronic antiplatelet therapy is safe and protective against acute ischemic events in patients with TA. Anticoagulant therapy, prednisone, immunosuppressive drugs and traditional risk factors for CVD did not seem to have influence on the incidence of ischemic events in TA. Most patients who were on antiplatelet therapy in the present study used a daily dose of aspirin between 100 and 200 mg, indicating that lower daily doses may be as effective as higher daily doses of aspirin such as 325 mg and 500 mg.
Inflammation, accelerated atherosclerosis and modification of laminar blood flow due to distortion of vessel wall anatomy may all contribute for the occurrence of arterial thrombosis and ischemic events in TA patients. Much attention has been given to platelet's role in those events as observed by the increased levels of TXB2, platelet factor 4 (PF4) and β-thromboglobulin in TA patients. 5,7,12 Nevertheless, other studies observed remarkable differences of TXB2 and P-selectin levels, and enhanced platelet aggregation only in active TA patients. 6, 8 To date, the only evidence of benefit with aspirin use in TA patients came from Numano et al who demonstrated that the upper limb affected by arterial stenosis had more platelet aggregation and higher levels of TXB2 when compared to the unaffected upper limb. The use of 80 mg of aspirin per day during one month led to the improvement of TXB2 levels and of platelet aggregation. 12 TA patients had higher plasma levels of thrombin-antithrombin III complex, fibrinopeptide A and D-dimer than healthy controls, indicating that other mechanisms besides isolated platelet activation may be responsible for the hypercoagulable state observed in TA. 5 Thromboembolic complications have been recognized as a concern in patients with systemic necrotizing vascultides other than TA. A higher rate of deep venous thrombosis has been observed in patients with ANCA-associated vasculitis while patients with giant cell arteritis (GCA) are at increased risk for developing arterial events such as cerebrovascular and cardiovascular events. 17-20 TA and GCA are large vessel 
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vasculitides that are considered clinically distinct conditions, although they share the involvement of the aorta and its main branches. In GCA, low-dose aspirin (75-150 mg/day) is recommended for all patients unless there is a contra-indication because it was shown to be effective in protecting against cardiovascular and cerebrovascular events. 21-22 These findings are in accordance with our observation that aspirin has a protective role against ischemic events in TA. In the present study, the only ischemic events observed in TA patients were cardiovascular and cerebrovascular events and, similarly to GCA, those events have been shown to be are preventable through aspirin use.
The frequency of bleeding complications in the present study was very low in patients on antiplatelet therapy. Only one patient out of 30 who were on aspirin experienced significant bleeding that may not have been related to aspirin use because this patient had a uterine myoma, which is a known cause of vaginal bleeding. Among patients on anticoagulant therapy, significant bleeding occurred in 2 out of 6 patients and they were only related to phenprocoumon use. Those findings indicate that besides being effective against ischemic events in TA patients, antiplatelet therapy was very safe and should be indicated to all TA patients in the absence of contraindications.
In the study, CVD risk factors did not seem to influence the occurrence of acute ischemic events. Although low HDL was found only in patients with ischemic events, its low frequency precludes us from drawing definite assumptions about this issue. Moreover, similarly to what had been previously observed in patients with GCA, statin therapy failed to prevent ischemic events in TA patients in the present study. 23 Nevertheless, accelerated atherosclerosis has been well recognized in TA patients either through autopsy studies or noninvasive methods. [24] [25] [26] [27] This finding has been highlighted by the higher frequency of risk factors for CVD such as systemic hypertension, high total cholesterol, low HDL and triglycerides in TA patients when compared to controls. 3,28,29 Moreover, TA patients had more endothelial dysfunction, lower paroxonase-1 activity, a higher proportion of large HDL2b and lower levels of HDL3b than in hypertensive patients and controls. 30 In clinical practice, the search for risk factors for CVD should not be overlooked in TA patients. Even though corticosteroid and immunosuppressive therapy was not associated with a protection against ischemic events in the present study, we believe that the proper treatment of TA disease activity is also important for preventing ischemic events altogether with aspirin use and the management of risk factors for CVD.
Limitations of the present study include its retrospective design, the lack of uniformity in data acquisition, the small sample size of TA patients and the small number of ischemic events, which limits the extraction of strong conclusions about the primary endpoint of the present study.
The results of our study indicate that antiplatelet therapy with aspirin dosage between 100-200 mg/day reduces the risk of acute ischemic events. Specially cerebrovascular and cardiovascular events in TA patients. Aspirin was well-tolerated and relatively safe with an almost null rate of bleeding complications.
